EricJ.LawitzMDFAASLD,AGAF,CPI

Gastroenterology • San Antonio, TX

Hepatology & Liver Transplantation

Texas Liver Institute University of Texas Health San Antonio

Join to view full profile

Dr. Lawitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lawitz's full profile

Already have an account?

Office
607 Camden St
Ste 108
San Antonio, TX 78215
Phone+1 210-253-3426

Fax+1 210-579-1252

Education & Training

San Antonio Uniformed Services Health Education ConsortiumFellowship, Gastroenterology, 1996 - 1999
San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1993 - 1996
Rush Medical College of Rush University Medical CenterClass of 1993

Certifications & Licensure

TX State Medical License 2003 - 2024
WI State Medical License 1995 - 2003
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

FAASLD Fellow of the American Association for the Study of Liver Diseases, 2016
FAPCR Fellow of the Academy of Physicians in Clinical Research, 2016
Fellow (AGAF) American Gastroenterological Association, 2012
CPI Certified Principal Investigator,Association of Clinical Research Professionals, 2004
Join now to see all

Clinical Trials

Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C Start of enrollment: 2006 May 01
Completed
Phase 1
TD-6450 MAD Study in HCV Infected Subjects Start of enrollment: 2014 May 01
Completed
Phase 1
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) Start of enrollment: 2014 Jul 28
Completed
Phase 2
Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4) Start of enrollment: 2014 Oct 01
Completed
Phase 1
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Start of enrollment: 2015 Jun 01
Completed
Phase 2
Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies Start of enrollment: 2016 Apr 30
Completed
Phase 2
A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants Start of enrollment: 2017 Jan 11
Withdrawn
Phase 1
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis Start of enrollment: 2017 Dec 27
Completed
Phase 2
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis Start of enrollment: 2018 Apr 25
Completed
Phase 2
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Start of enrollment: 2017 Aug 30
Completed
Phase 3
A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems Start of enrollment: 2019 Mar 06
Completed
Phase 1
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2019 Nov 19
Completed
Phase 2
A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects With Severe Renal Impairment and Normal Renal Function Start of enrollment: 2020 Jul 27
Recruiting
Phase 1
Roles: Principal Investigator, Contact
CM-101 in PSC Patients -The SPRING Study Start of enrollment: 2020 Oct 01
Active, not recruiting
Phase 2
Roles: Contact
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics Start of enrollment: 2022 Jan 03
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein Start of enrollment: 2023 Mar 06
Recruiting
Phase 3
Roles: Principal Investigator
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) Start of enrollment: 2024 Mar 01
Recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial.
Rohit Loomba, Pierre Bedossa, Katharine Grimmer, George Kemble, Eduardo Bruno Martins
The Lancet. Gastroenterology & Hepatology. 2024-12-01
105 citations
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Rohit Loomba, Manal F Abdelmalek, Matthew J Armstrong, Maximilian Jara, Mette Skalshøi Kjær
The Lancet. Gastroenterology & Hepatology. 2023-06-01
32 citations
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
Arun J Sanyal, Vlad Ratziu, Rohit Loomba, Quentin M Anstee, Kris V Kowdley
Journal of Hepatology. 2023-11-01

Journal Articles

The Lancet Child & Adolescent Health
Arun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet

Press Mentions

PharmaIN to Present Promising Interim Data from Its Ongoing Phase 1 Trial of PHIN-214, an Optimized Vasopressor for Decompensated Cirrhosis, at the Liver Meeting® 2024October 16th, 2024
HepQuant Results Presented While Attending the 72nd AASLD Annual Meeting and AHA 2021 Annual MeetingNovember 16th, 2021
Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVIDOctober 26th, 2021
Join now to see all